Event occurred in (b)(6).Overall, patient disease etiology was "prosthetic valve dysfunction - calcific" and tissue fragility resulting from re-operation.Patient had a re-do aortic valve replacement using on-x valve, resulted in paravalvular leak (pvl), post-operative-early.Nyha class ii.It was decided to not treat the pvl.The valve is being left in the patient with the observation during follow-up visits that there is on-going pvl, w/ moderate aortic regurgitation grade iii.The aats/sts guidelines defines pvl as valve-related and is reportable.Therefore, this is being reported.This is an expected adverse event and is occurring within expected rate.On (b)(6) 2015, onxlti received a set of data from the sponsor of a (b)(6) post-market study, where-in they wanted on-x to do data analysis on a set of data containing adverse events.The valve on this mdr is one of the ae's.Once analyzed against the entire population in the (b)(6) study (only avr has enough data for proper analysis) and then comparing to the pma.There are no statistically significant differences in these rates and this trail was run at inr of 1.5 to 2.5 versus the pma at 2.0 to 3.0.At lower inr low rates are expected based on our research.So these events while mdr reportable as individual occurrences, they are overall in the range expected.
|